Genmab

	5/7 16:00 af Solsen	Min håb er en lav rente og en tilbagekomst af TINA. Så har vi forudsætningen for kurs 3-4000.
	5/7 15:58 af Solsen	..i dag…
	5/7 15:57 af Solsen	@Helge i fag er der nogen analytikere fremme med vilde tal omkring olien (link)
	5/7 15:57 af bikube	Du mener: Solsen ved bedst.
	5/7 15:52 af bikube	Det må da snart være på tide, at vi hører fra "Monforte" angående hans Dara-maintenance. Jeg håber da, at det stadig går ham godt, men jeg ville gerne høre fra ham lidt oftere.
	5/7 15:38 af Helge Larsen/PI-redaktør	De fleste analytikere tror, at olien (brent) generelt holder sig over 100 dollar resten af 2022. :-)
	5/7 15:32 af Solsen	Råvarer og renter banker ned. Olien snart under $100 og analytikere spår yderligere fald. Hvede tilbage på niveauet før Ukraine krigen. Genmab i 3000 til jul ;-)
	5/7 14:52 af Sukkeralf	(link)
	5/7 14:52 af Sukkeralf	Probably wise to follow data from Teneo´s bispecifics - and a funny/unusually way they sell off programs:
	5/7 14:28 af E L	;-)
	5/7 14:19 af Sukkeralf	......yet another hope nohope :-)
	5/7 14:19 af Sukkeralf	Yes - otherwise we hope HexaBody CD38 can do the job
	5/7 14:16 af E L	great survey! looking forward to that maintenance data! many have been sceptical about maintenance (and about re-treating actually) so I would think that could still raise peak sales targets if data is good
	5/7 13:59 af nohope	Hope is not a strategy...
	5/7 13:34 af Sukkeralf	The position of Darzalex as both a key growth driver for Johnson & Johnson and anchor point for its longer-term ambitions in the MM market look set to remain undiminished.
	5/7 13:29 af Sukkeralf	Let us hope they are right :-)
	5/7 13:28 af Sukkeralf	A third of the physicians said they are extremely confident Darzalex will become an established maintenance therapy for MM based on its known clinical profile, with a further 53% describing themselves as being very confident of this outcome.
	5/7 13:28 af Sukkeralf	The primary outcome measure is percentage of patients achieving MRD-negative status with results anticipated next year.
	5/7 13:27 af Sukkeralf	oncurrently, Darzalex is also being evaluated as a potential maintenance treatment for MM. In the Phase III AURIGA trial, the combination of Darzalex plus Revlimid (lenalidomide) versus Revlimid alone is being studied as maintenance treatment in approximately 214 patients with newly diagnosed MM who are MRD positive following high-dose therapy (HDT) and autologous stem cell transplant (ASCT).
	5/7 13:27 af Sukkeralf	Ligeledes spændende:
	5/7 13:26 af Sukkeralf	Feedback from our poll overwhelmingly supports the assertion that MM patients can be re-treated with Darzalex, on the assumption that there has been an extended break in exposure to the drug. All 30 specialists said they are comfortable re-treating patients with Darzalex in these circumstances, with 50% of respondents describing themselves as 'very' comfortable with this approach and 37% as 'extremely' comfortable.
	5/7 13:25 af Sukkeralf	Data from Johnson & Johnson's Phase II LYNX study, which due to readout late this year or in early 2023, could provide some answers. This trial is evaluating Darzalex in combination with Kyprolis (carfilzomib) and dexamethasone (Kd), versus Kd alone, in approximately 230 patients that have received one to three prior lines of therapy, one of which contained Darzalex.
	5/7 13:25 af Sukkeralf	Det bliver spændende:
	5/7 13:22 af Sukkeralf	Johnson & Johnson's mAb looks set to win on all fronts over the next few years in the multiple myeloma market.

	5/7 13:21 af Sukkeralf	(link)
	5/7 13:21 af Sukkeralf	Tror ikke der har været linket til denne:
	5/7 12:53 af ProInvestorNEWS	:-D
	5/7 12:22 af ProInvestorNEWS	Aktier/middag: C25 tynges af makrousikkerhed - SAS i tocifret fald (link)
	5/7 11:18 af bikube	Og $ flyver højt 7,21.
	5/7 10:47 af Bulder	Lidt mystisk hvis det der det. Faldt til 52. Ventet 51,9
	5/7 10:47 af Helge Larsen/PI-redaktør	Reguleringen var endda til den positive side.
	5/7 10:45 af Helge Larsen/PI-redaktør	Der var vist en efterregulering på europæisk PMI kl. 10. Den burde ikke kunne rykke markederne i noget særligt omfang.
	5/7 10:43 af Bulder	Genmab er oppe som nr 2 på c25 vinderlisten.
	5/7 10:43 af Helge Larsen/PI-redaktør	:-)
	5/7 10:41 af Bulder	Heldigvis lå genmab så højt, at der var noget "at tage af".
	5/7 10:38 af Helge Larsen/PI-redaktør	Selv Oslo reagerede negativt.
	5/7 10:37 af Helge Larsen/PI-redaktør	Ja..Det var tydeligt at se.
	5/7 10:27 af Bulder	Der skete et eller andet kl 10.05. Futterne og c25 er gået i rødt. alting falder nu.
	5/7 10:21 af E L	interesting point on the charts here where we are at the downtrend line starting from November? All small resistance since the low were broken very easily so far...
	5/7 10:15 af Stroka	Trenden er stærk i dag. Aktien ender måske ligefrem med at være at være i plus for 2022 midt i juli. :-)
	5/7 08:57 af JKY_VH	Tak E L
	5/7 08:42 af ProInvestorNEWS	Aktier/tendens: Sandsynligt stigende aktieindeks trods SAS-strejke (link)
	5/7 08:40 af E L	Deutsche Bank analyst Emmanuel Papadakis reiterated a Buy rating and DKK2,750.00 price target on Genmab
	5/7 07:09 af ProInvestorNEWS	Aktier: VIX indekset er som mavepinen, som ikke vil gå væk (link)
	5/7 06:38 af Stroka	God morgen. :-)
	5/7 06:35 af Helge Larsen/PI-redaktør	God morgen. :-)
	4/7 17:30 af JKY_VH	Jeg tror du tager spurten Solsen;-)
	4/7 16:21 af Solsen	Jeg har hedget med panodiler til dagen efter. En af os må have taget fejl af menuen :-)
	4/7 13:42 af nohope	Uha - bare jeg da ikke skal ligge vågen hele natten og være bekymret for det. Jeg har heldigvis hedget det med 6 stk, 2 liters danskvand med citronsmag.
	4/7 13:02 af Helge Larsen/PI-redaktør	:-D